Kristin Anderson, MPH; Judith S. Jacobson, DrPH, MBA; Daniel F. Heitjan, PhD; Joshua Graff Zivin, PhD; Dawn Hershman, MD; Alfred I. Neugut, MD, PhD; Victor R. Grann, MD, MPH
Grant Support: By a research scholar grant from the American Cancer Society (RSGHP-03-166-01-PBP). Drs. Hershman and Neugut are the recipients of a K07 Award (CA-95597) and a K05 Award (CA89155), respectively, from the National Cancer Institute.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Victor R. Grann, MD, MPH, Mailman School of Public Health, Columbia University, Room 734, 722 West 168th Street, New York, NY 10032; e-mail, VRG2@columbia.edu.
Current Author Addresses: Ms. Anderson: Medical School Duluth, University of Minnesota, Duluth, School of Medicine 113, 1035 University Drive, Duluth, MN 55812-3031.
Drs. Jacobson and Graff Zivin: Columbia University, 722 West 168th Street, New York, NY 10032.
Dr. Heitjan: Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104-6021.
Dr. Hershman: Herbert Irving Comprehensive Cancer Center, 161 Fort Washington Avenue, Room AP-1068, New York, NY 10032.
Drs. Neugut and Grann: Mailman School of Public Health, Columbia University, Room 734, 722 West 168th Street, New York, NY 10032.
Author Contributions: Conception and design: K. Anderson, D.F. Heitjan, J. Graff Zivin, D. Hershman, A.I. Neugut, V.R. Grann.
Analysis and interpretation of the data: K. Anderson, J.S. Jacobson, D.F. Heitjan, D. Hershman, A.I. Neugut, V.R. Grann.
Drafting of the article: K. Anderson, J.S. Jacobson, D. Hershman, V.R. Grann.
Critical revision of the article for important intellectual content: K. Anderson, J.S. Jacobson, D.F. Heitjan, J. Graff Zivin, D. Hershman, A.I. Neugut, V.R. Grann.
Final approval of the article: K. Anderson, J.S. Jacobson, D.F. Heitjan, J. Graff Zivin, D. Hershman, A.I. Neugut, V.R. Grann.
Provision of study materials or patients: K. Anderson, V.R. Grann.
Statistical expertise: K. Anderson, D.F. Heitjan, V.R. Grann.
Obtaining of funding: K. Anderson, V.R. Grann.
Administrative, technical, or logistic support: K. Anderson, V.R. Grann.
Collection and assembly of data: K. Anderson.
Anderson K., Jacobson J., Heitjan D., Zivin J., Hershman D., Neugut A., Grann V.; Cost-Effectiveness of Preventive Strategies for Women with a BRCA1 or a BRCA2 Mutation. Ann Intern Med. 2006;144:397-406. doi: 10.7326/0003-4819-144-6-200603210-00006
Download citation file:
Published: Ann Intern Med. 2006;144(6):397-406.
Germline mutations account for 5% to 10% of breast cancer diagnosed in the United States each year (1). Because women who develop cancer associated with such mutations do so at a relatively young age, these mutations account for a disproportionate share of life-years lost due to cancer. Genetic testing is expensive, but so is cancer. Hence, cost-effective policies on testing and preventive treatment options may save up to $800 million of the more than $8 billion or more spent each year on breast cancer diagnosis, prevention, and treatment (2-4).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Healthcare Delivery and Policy, Breast Cancer, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only